| Lipid modulation and liver function tests. A report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). | |
| | |
MedLine Citation:
|
PMID: 12006915 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Statin drugs are known to cause dose-dependent abnormalities in liver function tests (LFTs), with elevations three times the upper limits of normal of the aminotransferase enzymes in up to 2.5% of patients on the highest prescribable doses. The Program on the Surgical Control of the Hyperlipidemias (POSCH) trial employed no hypocholesterolaemic drugs and used a surgical procedure, partial ileal bypass, as the intervention modality. METHODS: Serum total bilirubin, alkaline phosphatase and serum glutamic-oxaloacetic transaminase (SGOT) (equivalent to aspartate aminotransferase [AST]), were the LFTs obtained in POSCH at baseline, 3 months, annually for 5 years, and at 7 or 10 years postrandomization. RESULTS: Abnormal values were found for total bilirubin in seven of 416 control group (CG) patients (1.68%) and in 34 of 373 intervention group (IG) patients (9.16%) (P = 0.001); for alkaline phosphatase, in 28 of 378 (7.41%) and in 41 of 326 (12.58%) (P = 0.0214); and for SGOT, in 102 of 412 (24.76%) and in 161 of 372 (43.28%) (P = 0.001). Values twice the upper limit of normal occurred in 1 CG and 1 IG patient for total bilirubin and for alkaline phosphatase, and in 11 CG and 7 IG patients for SGOT (NS). Values three times the upper limit of normal did not occur in any patient for total bilirubin or alkaline phosphatase, and occurred in 3 CG and 5 IG patients for SGOT (NS). CONCLUSIONS: In POSCH, the IG demonstrated statistically significant mild increases for total bilirubin, alkaline phosphatase and SGOT levels, with no significant increases in values twice or greater the upper limits of normal. |
| | |
Authors:
|
Henry Buchwald; Stanley E Williams; John P Matts; James R Boen |
Related Documents
:
|
7572155 - Type la glycogen storage disease with focal nodular hyperplasia in siblings. 978335 - Reversible oxacillin hepatotoxicity. 21176915 - Venous thromboembolic disease in trauma and surveillance ultrasonography. 920245 - Acute hepatitis: a prognostic study with observation time up to 37 years. a follow-up o... 15316125 - Clinical features of adult-onset ankylosing spondylitis in korean patients: patients wi... 17398185 - Usefulness of 64-slice multidetector computed tomography in diagnostic triage of patien... |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. |
Journal Detail:
|
Title: Journal of cardiovascular risk Volume: 9 ISSN: 1350-6277 ISO Abbreviation: J Cardiovasc Risk Publication Date: 2002 Apr |
Date Detail:
|
Created Date: 2002-05-13 Completed Date: 2002-06-28 Revised Date: 2007-11-14 |
Medline Journal Info:
|
Nlm Unique ID: 9436980 Medline TA: J Cardiovasc Risk Country: England |
Other Details:
|
Languages: eng Pagination: 83-7 Citation Subset: IM |
Affiliation:
|
Department of Surgery, University of Minnesota, Minneapolis, Minnesota 55455, USA. buchw001@umn.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Alkaline Phosphatase
/
blood Aspartate Aminotransferases / blood Bilirubin / blood Female Follow-Up Studies Humans Hyperlipidemias / blood*, surgery* Lipids / blood* Liver Function Tests* Male Reference Values |
| Grant Support | |
ID/Acronym/Agency:
|
R01-HL-15265/HL/NHLBI NIH HHS; R01-HL-49522/HL/NHLBI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Lipids; 635-65-4/Bilirubin; EC 2.6.1.1/Aspartate Aminotransferases; EC 3.1.3.1/Alkaline Phosphatase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Is carotid artery intima-media thickening a reliable marker of early atherosclerosis?
Next Document: Declaring war on undertreatment: rationale for an aggressive approach to lowering cholesterol.